Published on : Mar 30, 2016
Non-small cell lung cancer, better known as NSCLC, accounts for 85-90% of all lung cancers. The three major subtypes of NSCLC include adenocarcinoma, large cell carcinoma, and squamous cell carcinoma. The global non-small cell lung cancer therapeutics market is estimated to be propelled by the growing demand for angiogenesis inhibitors. The non-small cell lung cancer is quite insensitive to chemotherapy. Based on drug class, the global NSCLC market has been segmented into epidermal growth factor receptor blocker, microtubule stabilizer, angiogenesis inhibitor, kinase inhibitor, PD-1/PD-L1 inhibitor, and folate antimetabolites. The surging demand for angiogenesis inhibitor is expected to define the future outlook of the market.
Innovative Approach to Treat Acute Myeloid Leukaemia
A number of players such as Bristol-Myers Squibb, Genentech Inc. (a Roche Company), Boehringer Ingelheim, Pfizer Inc., Eli Lilly and Company, Astra Zeneca plc, Novartis AG, and Celgene Corporation are developing therapeutics for non-small cell lung cancer market. The overall cancer therapeutics market is anticipated to be boosted by the partnership between the Harvard University and pharmaceutical firm Merck. The novel compounds developed in the laboratory at the University would propose an innovative approach to treat the disease by targeting the enzymes that regulate transcription. In 2015, acute myeloid leukaemia, better known as AML, was the most prevalent in the United States with around 20,800 new reported cases. The disease is responsible for the largest number of leukaemia-related deaths with a very low survival rate. The University has proposed to treat the disease by inhibiting the enzymes that regulate the transcription of the key genetic programs. These genetic programs are altered in case of AML and other types of cancer. Merck will take over the development of the candidate therapeutics and will partner with the University to find out the biology of transcriptional regulator enzymes.